OGN Organon & Co.

Why MIUDELLA’s FDA review matters for Organon stock Organon (OGN) just picked up fresh attention after the FDA accepted a supplemental application to extend use of MIUDELLA, a copper IUD that Organon licensed globally earlier this year. The device is already indicated for pregnancy prevention for up to 3 years, with an extended duration review underway and commercial availability targeted for late 2026. For investors watching Organon stock, this product sits squarely in the women’s health...

Organon (NYSE: OGN) received FDA acceptance to review a supplemental New Drug Application for its hormone free contraceptive device MIUDELLA. The company entered an exclusive global licensing agreement for MIUDELLA, aiming to expand access to hormone free contraception across markets. Organon plans commercial availability of MIUDELLA as a longer duration contraceptive option, subject to regulatory review outcomes and launch execution. Beyond the MIUDELLA sNDA review and new global license,...

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Investors hammered Cooper Companies on Thursday after the medtech's fiscal third-quarter sales lagged Wall Street's expectations.

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Organon (OGN) delivered earnings and revenue surprises of -2.30% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

By Kashish Tandon July 31 (Reuters) - India's Sun Pharmaceutical Industries reported a 27% rise in first-quarter profit on Friday, driven by robust growth in its high-margin specialty medicines

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting. The special meeting was convened solely to cons

Leadership change in Canada puts Organon (OGN) in focus Organon (OGN) is back on investors’ radar after Organon Canada appointed Dominic Bégin as President and Managing Director, a leadership move that could influence how the company prioritizes its Canadian growth plans. See our latest analysis for Organon. For context, Organon’s share price is US$13.52, with a 90 day share price return of 57.21% and an 86.74% year to date share price return. The 3 year total shareholder return has declined...

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.